88 related articles for article (PubMed ID: 28749002)
1. [Natalizumab for the treatment of Crohns disease: Report of three cases].
Fluxá D; Ibáñez P; Flores L; Figueroa C; Lubascher J; Kronberg U; Simian D; Pizarro G; Toche P; Quera R
Rev Med Chil; 2017 Apr; 145(4):538-543. PubMed ID: 28749002
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
Bellaguarda E; Keyashian K; Pekow J; Rubin DT; Cohen RD; Sakuraba A
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1919-25. PubMed ID: 26001336
[TBL] [Abstract][Full Text] [Related]
3. Real World Experience With Natalizumab at a Tertiary Care Pediatric IBD Center.
Singh N; Deshpande R; Rabizadeh S; Dubinsky M
J Pediatr Gastroenterol Nutr; 2016 Jun; 62(6):863-6. PubMed ID: 27213249
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab in the treatment of Crohn's disease patients.
Pagnini C; Arseneau KO; Cominelli F
Expert Opin Biol Ther; 2017 Nov; 17(11):1433-1438. PubMed ID: 28832222
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
Sakuraba A; Keyashian K; Correia C; Melek J; Cohen RD; Hanauer SB; Rubin DT
Inflamm Bowel Dis; 2013 Mar; 19(3):621-6. PubMed ID: 23429449
[TBL] [Abstract][Full Text] [Related]
7. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab for Crohn's Disease: Down but Not Out.
Scott FI; Osterman MT
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1926-8. PubMed ID: 26196443
[No Abstract] [Full Text] [Related]
9. Failure to Account for Immortal Person Time Likely Accounts for the Apparent Reduction in Surgery Among Natalizumab Users.
Targownik LE
Clin Gastroenterol Hepatol; 2016 May; 14(5):776. PubMed ID: 26614877
[No Abstract] [Full Text] [Related]
10. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
McLean LP; Cross RK
Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
Hyams JS; Wilson DC; Thomas A; Heuschkel R; Mitton S; Mitchell B; Daniels R; Libonati MA; Zanker S; Kugathasan S;
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
[TBL] [Abstract][Full Text] [Related]
12. Reply.
Bellaguarda E; Sakuraba A
Clin Gastroenterol Hepatol; 2016 May; 14(5):776-7. PubMed ID: 26853161
[No Abstract] [Full Text] [Related]
13. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience.
Kane SV; Horst S; Sandborn WJ; Becker B; Neis B; Moscandrew M; Hanson KA; Tremaine WJ; Bruining DH; Faubion WA; Pardi DS; Harmsen WS; Zinsmeister AR; Loftus EV
Inflamm Bowel Dis; 2012 Dec; 18(12):2203-8. PubMed ID: 22419661
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals.
Juillerat P; Wasan SK; Fowler SA; Friedman S; Pabby VK; Coukas JA; Barto AE; Pellish R; Germansky KA; Cheifetz AS; Korzenik JR; Farraye FA; Yajnik V
Inflamm Bowel Dis; 2013 Oct; 19(11):2457-63. PubMed ID: 23962896
[TBL] [Abstract][Full Text] [Related]
15. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review.
Scribano ML; Cantoro L; Marrollo M; Cosintino R; Kohn A
J Clin Gastroenterol; 2014 Jul; 48(6):530-3. PubMed ID: 24667589
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
17. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
[TBL] [Abstract][Full Text] [Related]
18. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
19. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
20. Update on idiopathic colitides.
Strobel S; Abreu MT
Curr Opin Gastroenterol; 2013 Jan; 29(1):60-5. PubMed ID: 23207597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]